Contract analysis

From: Leonard Cross <lcross@calderwoodharkness.com> To: Marcus Whitfield <mwhitfield@penterra.com> Cc: Sylvia Hartwell <shartwell@calderwoodharkness.com> Date: Mon, 22 Apr 2024 10:47:00 -0000 Subject: APA Consideration — Bilateral U.S.-Ireland Advance Pricing Agreement for Future Tax Years

I hope this finds you well. Please find attached our memorandum dated April 20, 2024, analyzing whether Penterra Pharmaceutical Corp. should pursue a bilateral advance pricing agreement (APA) with the IRS and Irish Revenue. This follows naturally from the successful resolution of the IRS examination (Matter No. 1018-00009) and the going-forward transfer pricing recommendations we transmitted to you on April 15.

I want to emphasize at the outset that this is a recommendation for your team's consideration rather than an urgent action item. That said, I think the case for exploring an APA is compelling, and I wanted to put the analysis in front of you while the examination experience is still fresh.

As you know, the IRS examination of TY 2017–2020 resulted in a proposed adjustment of $380.4 million, which we ultimately resolved at IRS Appeals for $47.6 million — approximately 12.5% of the proposed amount — via the Form 906 Closing Agreement executed on March 29, 2024. By any measure, the outcome was highly favorable. The total cash cost of approximately $12.84 million (tax of $10.0 million plus interest of appro

However, the examination also consumed significant time and resources over nearly two years: 47 IDRs, substantial management attention, and total professional fees of approximately $8.3 million (Calderwood Harkness fees of $5,837,420; Whitmore Valuation Group fees of $2,146,800; and Thornbury & Keogh coordination fees of approximately $341,200). Given that PPC's cost-sharing arrangement with Penterra Biopharma Intern

**Summary of Key Points from the Memorandum**

The attached memo covers the following in detail, but I want to highlight the key considerations here:

*Bilateral APA Process.* The APA would involve a simultaneous application to the IRS (under Rev. Proc. 2015-41 and the APA program guidance) and to Irish Revenue, leveraging the mutual agreement procedure (MAP) provisions of the U.S.-Ireland Income Tax Treaty. The bilateral structure is important because it would bind both taxing authorities and effectively eliminate the risk of double taxation.

*Scope.* We would anticipate covering the intercompany royalty rate for legacy IP (currently 4.5% of net sales), the cost-sharing arrangement percentages and methodology under Treas. Reg. § 1.482-7, and potentially the contract manufacturing markup for Penterra Manufacturing Ireland Ltd. (currently cost + 8%). Covering all three intercompany transactions in a single application is typically more efficient than addres

*Advantages.* The principal benefits include: (1) prospective certainty on transfer pricing methodology for typically five years, with possible rollback to prior open years; (2) avoidance of future multi-year examinations of the kind we just concluded; (3) reduced professional fees over the APA term relative to examination defense; (4) improved FIN 48/ASC 740-10 reserve posture — your current post-settlement reserve

*Disadvantages and Risks.* These should not be understated. The upfront cost is significant (the APA user fee plus professional fees to prepare the application are estimated in the memo). Bilateral APAs typically take two to four years to negotiate and conclude. The process requires full disclosure of PPC's transfer pricing methodology and financial projections to both the IRS and Irish Revenue, which goes well beyon

*Coordination with Thornbury & Keogh.* Ciarán Thornbury and T&K would need to be closely involved on the Irish Revenue side of a bilateral application. Leila Nazari on our team recently coordinated with T&K on competent authority and MAP considerations in connection with the examination resolution, and that working relationship is well-established.

*Whitmore Valuation Group.* Dr. Helena Vasquez and her team would likely be needed to prepare the economic analysis supporting the APA application, building on the existing benchmarking studies (the 14 CUT comparables, 22 CPM/TNMM comparables, and the PCT DCF analysis). Much of the foundational work has been done, which should reduce the incremental effort.

I would recommend scheduling a call with you, Deborah, and CFO Rajesh Iyer — and potentially Catherine Falk as well, given the strategic nature of the decision — to discuss whether PPC wishes to proceed. If PPC is interested in principle, we would prepare a detailed scope-and-budget proposal for the APA engagement, which would be opened as a separate matter from 1018-00009.

There is no immediate deadline — the APA application can be filed at PPC's discretion — but I would suggest that initiating the process before TY 2021 returns come under potential examination would be advantageous, both from a timing perspective and in terms of signaling to LB&I.

We are also happy to coordinate a preliminary discussion with T&K in Dublin regarding Irish Revenue's appetite for a bilateral process, which would help inform PPC's decision without committing to proceed.

One additional note: you should also consider the interaction between an APA and the substance-enhancement recommendations that Garrett Simmons transmitted to you earlier today. Strengthened operational substance at PBI would meaningfully support the economic analysis underlying an APA application, and the two workstreams would ideally be coordinated.

I am available to discuss any of this at your convenience. If schedules permit, a call the week of April 29 would be ideal.

Leonard Cross Partner Calderwood Harkness LLP 1200 Connecticut Avenue NW, Suite 800 Washington, DC 20036 (202) 555-4180 lcross@calderwoodharkness.com

*CONFIDENTIALITY NOTICE: This email and any attachments are for the exclusive and confidential use of the intended recipient. This communication is protected by the attorney-client privilege and/or the work product doctrine. If you are not the intended recipient, please do not read, distribute, or take action based on this message. If you have received this communication in error, please notify the sender immediately